ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "patient"

  • Abstract Number: 2050 • 2016 ACR/ARHP Annual Meeting

    Screening for and Management of Comorbidities after a Nurse-Led Program: Results of a 3 Year Longitudinal Study in 776 Established RA Patients

    Laure Gossec1, Martin Soubrier2, Frantz Foissac3, Anna Molto4, Françoise Fayet5, Thomas Bardin6, Francis Berenbaum7, Alain Cantagrel8, Marie Hélène Cerato9, Gerard H. Chales10, Bernard Combe11, Emmanuelle Dernis Labous12, Isabelle Chary-Valckenaere13, Liana Euller-Ziegler14, Rene-Marc Flipo15, Philippe Gaudin16, Melanie Gilson17, Sandrine Guis18, Xavier Mariette19, Gaël Mouterde20, Sophie Pouplin21, Pascal Richette22, Alain Saraux23, Thierry Schaeverbeke24, Jean Sibilia25 and Maxime Dougados26, 1Rheumatology, Pitié Salpêtrière Hospital, Paris, France, 2Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, 3COMEDRA working group, Paris, France, 4Hopital Cochin, Paris Descartes University, Paris, France, 5Rheumatology, CHU Gabriel-Montpied, Clermont-Ferrand, France, 6Hôpital Lariboisière, Paris, France, 7Rheumatology dept, APHP St-Antoine hospital, Univ Paris 06, Paris, France, Paris, France, 8Purpan Hospital, Toulouse, France, 9University Hospital, Toulouse, France, 10CHU RENNES, Rennes, France, 11Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 12Le Mans Hospital, Le Mans, France, 13University Hospital, Nancy, France, 14Rheumatology, Nice, France, 15Rheumatology, University Hospital, Lille, France, 16Rheumatology, Grenoble University Hospital, France, Grenoble, France, 17Hopital Sud, Grenoble, France, 18Rheumatology 1, CRMBM-CEMEREM 7339, Aix-Marseille Université, AP-HM, CNRS, Marseilles, France, 19Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France, 20Rheumatology Department, Hopital Lapeyronie, Montpellier, France, 21Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, 22Rhumatologie, Hôpital Lariboisière, Paris, France, 23Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, 24Rheumatology, CHU Bordeaux, Bordeaux, France, 25Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 26Paris Descartes University, Paris, France

    Background/Purpose: Patients with RA are either more at risk of, or less well screened for, several comorbidities including cardiovascular (CV) risk, cancer, infections and osteoporosis.[1]…
  • Abstract Number: 363 • 2016 ACR/ARHP Annual Meeting

    An Examination of Patient Knowledge and Education in Patients with Osteoporosis, Osteopenia and Normal Bone Mineral Density

    Shazia Beg1 and Ahdad Ziyar2, 1University of Central Florida College of Medicine, Orlando, FL, 2University of Central Florida, Orlando, FL

    Background/Purpose: Osteoporosis represents a preventable and often treatable condition that is responsible for 1.5 million fractures annually in the United States. Proper patient knowledge represents…
  • Abstract Number: 2084 • 2016 ACR/ARHP Annual Meeting

    Effects of a Web-Based Patient Decision Aid on Biologics for Rheumatoid Arthritis: A Proof-of-Concept Study

    Linda Li1, Chris Shaw2, Diane Lacaille1, Elaine Yacyshyn3, C. Allyson Jones4, Paul Adam5, Cheryl Koehn6, Alison Hoens7, Jasmina Geldman8, Charles Goldsmith9, Eric C. Sayre8 and Nick Bansback10, 1Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, 2School of Interactive Arts and Technology, Simon Fraser University, Surrey, BC, Canada, 3University of Alberta, Edmonton, AB, Canada, 4Physical Therapy, University of Alberta, Edmonton, AB, Canada, 5Mary Pack Arthritis Program, Vancouver, BC, Canada, 6Arthritis Consumer Experts, Vancouver, BC, Canada, 7Dept of Physical Therapy, University of British Columbia, Vancouver, BC, Canada, 8Arthritis Research Canada, Richmond, BC, Canada, 9Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada, 10School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose : Under the treat-to-target approach for patients with rheumatoid arthritis (RA), a biologic agent is considered when the target is not met despite trying…
  • Abstract Number: 421 • 2016 ACR/ARHP Annual Meeting

    Educating Patients on the  Cardiovascular Risks of Rheumatoid Arthritis: Usual Care Versus a Structured Approach

    Marcia Genta1 and Robert M. Genta2, 1Dallas Arthritis Center, Dallas, TX, 2Laboratory, Dallas Arthritis Center, Dallas, TX

    Background/Purpose: Rheumatoid Arthritis (RA) carries a considerable increase of the risks for cardiovascular (CV) disease. It is unclear how well patients with RA understand such…
  • Abstract Number: 2239 • 2016 ACR/ARHP Annual Meeting

    Patterns of Abatacept Utilization in Patients with Rheumatoid Arthritis. Have the Baseline Characteristics of These Patients Changed over Time?

    M. Victoria Hernández1, Carlos Sánchez-Piedra2, Jose Inciarte-Mundo1, Fernando Sanchez-Alonso2, Javier Manero3, Rosa Roselló4, Eva Pérez-Pampin5, Rosa Morla6, Carlos Rodriguez-Lozano7, Dolores Ruiz-Montesinos8, Raimon Sanmarti1, Juan J. Gómez-Reino5 and BIOBADASER 2.0 Study Group, 1Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, 2Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 3Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, 4Rheumatology, H San Jorge, Huesca, Spain, 5Rheumatology, Hospital Clínico Universitario. Santiago de Compostela, Santiago de Compostela, Spain, 6Arthritis Unit. Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, 7Rheumatology, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, 8Rheumatology, Hospital Virgen Macarena, Seville, Spain

    Background/Purpose:  Abatacept (ABA), a T cell co-stimulation inhibitor, was initially approved by the European Medicine Agency (EMA) for patients with rheumatoid arthritis (RA) who had…
  • Abstract Number: 456 • 2016 ACR/ARHP Annual Meeting

    Patient Engagement in Research: Understanding Patient Interest and Needs

    Jennifer R. Horonjeff1, Emily L. Creek2 and Cindy McDaniel3, 1Rheumatology, Columbia University Medical Center, New York, NY, 2Consumer Health, Arthritis Foundation, Atlanta, GA, 3Arthritis Foundation, Atlanta, GA

    Background/Purpose: The goal of clinical and health-related research is to benefit the end-consumer—the patient. Since patients are the experts on their unique experiences living with…
  • Abstract Number: 2533 • 2016 ACR/ARHP Annual Meeting

    Are There Differences in Baseline Comorbidities Between Rheumatoid Arthritis Patients Treated with Abatacept and Those Treated with Tumor Necrosis Factor Inhibitors?

    M. Victoria Hernández1, Carlos Sánchez-Piedra2, Jose Inciarte-Mundo1, Fernando Sanchez-Alonso2, Javier Manero3, Rosa Roselló4, Eva Pérez-Pampin5, Carlos Rodriguez-Lozano6, Cesar Diaz-Torné7, Raimon Sanmarti1, Juan J. Gómez-Reino5 and Biobadaser 2.0 Study Group, 1Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, 2Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 3Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, 4Rheumatology, H San Jorge, Huesca, Spain, 5Rheumatology, Hospital Clínico Universitario. Santiago de Compostela, Santiago de Compostela, Spain, 6Rheumatology, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, 7Rheumatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

    Background/Purpose:  Rheumatoid arthritis (RA) patients frequently report concomitant comorbidities that could worsen their prognosis. Tumor necrosis factor inhibitors (TNFi), the most common biological agents used,…
  • Abstract Number: 628 • 2016 ACR/ARHP Annual Meeting

    Analysis of Baseline Characteristics of Rheumatoid Arthritis Patients Treated with Abatacept Compared to Those Treated with Tumor Necrosis Factor Inhibitors in Clinical Practice

    M. Victoria Hernández1, Carlos Sánchez-Piedra2, Juan D. Cañete1, Fernando Sanchez-Alonso2, Javier Manero3, Ana M. Ortiz Garcia4, Eva Pérez-Pampin5, Rosa Roselló6, Carlos Rodriguez-Lozano7, Raimon Sanmarti1, Juan J. Gómez-Reino5 and BIOBADASER 2.0 Study Group, 1Rheumatology Department, Hospital Clínic de Barcelona, Barcelona, Spain, 2Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 3Rheumatology, Hospital Miguel Servet, Zaragoza, Spain, 4Rheumatology, Rheumatology Service, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, 5Rheumatology, Hospital Clínico Universitario. Santiago de Compostela, Santiago de Compostela, Spain, 6Rheumatology, H San Jorge, Huesca, Spain, 7Rheumatology, Hospital de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain

    Background/Purpose: Currently, the most widely used biological agents for rheumatoid arthritis (RA) patients are the inhibitors of the tumor necrosis factor (TNFi), although other biological…
  • Abstract Number: 3130 • 2016 ACR/ARHP Annual Meeting

    Development and Pilot Testing of an Online Educational Tool for Gout Patients — Mygoutcare®

    Puja Khanna1, Aaron Rankin2, Veronica Berrocal3, Larry An4 and Dinesh Khanna5, 1Rheumatology, University of Michigan, Ann Arbor, MI, 2Medicine Rheumatology, University of Michigan, Ann Arbor, MI, 3Biostatistics, University of Michigan, Ann Arbor, MI, 4Medicine, University of Michigan, Ann Arbor, MI, 5University of Michigan, Ann Arbor, MI

    Background/Purpose:  Recent management guidelines for gout have identified several unmet educational needs in gout patients. Qualitative studies have documented the paucity of patient-focused materials which…
  • Abstract Number: 903 • 2016 ACR/ARHP Annual Meeting

    Temporal Arteritis: Is There Any Correlation Between Ultrasonographic Arterial Wall Involvement and the Inflammatory Cellular Infiltrate at Histological Examination?

    Giuseppe Germanò1, Pierluigi Macchioni2, Alberto Cavazza3, Niccolò Possemato2, Mariagrazia Catanoso4, Luca Cimino5 and Carlo Salvarani6, 1Unit of Rheumatology, Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Italy, 2Rheumatology Service, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 3Pathology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, 4Rheumatology Service, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, 5Ophthalmology Unit, Arcispedale S Maria Nuova-IRCCS, Reggio Emilia, Italy, 6Rheumatology Unit, Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy

    Background/Purpose: Ultrasonographic alterations such as the halo sign and the compression test are now accepted as surrogate markers of artery inflammation. No data have yet…
  • Abstract Number: 981 • 2016 ACR/ARHP Annual Meeting

    Effectiveness of a Six-Week Hand Osteoarthritis Program in a Primary Care Setting

    Nina Brodin1,2, Linda Bjurehed3 and Mathilda Björk4,5, 1Department of Neurobiology, Care Sciences and Society, Division of Physiotherapy, Karolinska Institutet, Huddinge, Sweden, 2Department of Orthopaedics, Division of Physiotherapy, Dandeyd Hospital, Stockholm, Sweden, 3Department of Activity and Health, Linköping, Linköping University Hospital, Linköping, Sweden, 4Department of Rheumatology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, 5Department of Rheumatology and Department of Social and Welfare Studies, Linköping University, Linköping, Sweden

    Background/Purpose:  Hand Osteoarthritis (hand OA) is highly prevalent among women and men aged 55 and older. It often causes pain, reduced range of motion and…
  • Abstract Number: 1146 • 2016 ACR/ARHP Annual Meeting

    Reducing Imaging Tests for Low Back Pain: Can Patients Choose Wisely?

    Nick Bansback1, Judy Chiu2, Sheila Kerr3, Rita McCracken2,4 and Bruce Forster5, 1School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada, 2Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada, 3Arthritis Patient Advisory Board, Richmond, BC, Canada, 4Family Practice, University of British Columbia, Vancouver, BC, Canada, 5Professor and Head, Department of Radiology, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Management of nonspecific acute low back pain (LBP) is complicated by many patients' belief that imaging tests will be useful. Choosing Wisely is a campaign…
  • Abstract Number: 1153 • 2016 ACR/ARHP Annual Meeting

    Exploring Perceptions of a Rheumatoid Arthritis Specific Smoking Cessation Programme

    Pip Aimer1, Lisa K. Stamp2, Simon Stebbings3, Vicky Cameron1, Sandra Kirby4 and Gareth Treharne5, 1Medicine, University of Otago, Christchurch, New Zealand, 2University of Otago, Christchurch, New Zealand, 3Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand, 4Arthritis New Zealand, Wellington, New Zealand, 5Psychology, University of Otago, Dunedin, New Zealand

    Background/Purpose: Premature mortality rates in individuals with rheumatoid arthritis (RA) are significantly higher in current smokers compared to those who have never smoked, making smoking…
  • Abstract Number: 1158 • 2016 ACR/ARHP Annual Meeting

    Effects of an Educational Program Using Treat to Target Strategy in Korean Patients with  Rheumatoid Arthritis

    SeungIn Paek1, Seo Hwa Kim2, Haneul Kim3, Min Kyung Chung4, Jennifer Lee5, Seung-Ki Kwok6, Ji Hyeon Ju7, Sung-Hwan Park7 and Kyeong Yae Sohng8, 1Center for Rheumatic Diseases, Seoul ST Mary's Hospital, The Catholic University of Korea, Seoul, South Korea, 2Division of Rheumatology,, Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, 3Division of Rheumatology,, Department of Internal Medicine, School of Medicine, The Catholic University of Korea, Seoul St. Mary’s Hospital, Seoul, Republic of Korea, Seoul, Korea, The Republic of, 4Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, The Republic of, 5Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 6[email protected], Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 7Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 8College of Nursing, The Catholic University of Korea, Seoul, South Korea

    Background/Purpose: The purpose of this study was to investigate the effects of an educational program using T2T (Treat RA to Target, T2T) strategy on Korean…
  • Abstract Number: 1163 • 2016 ACR/ARHP Annual Meeting

    Impact of E-Learning on Perceived Social Role Participation of Patients with Axial Spondyloarthritis: Results from a Longitudinal Randomized Control Trial

    Daeria Lawson1, Laura Passalent2,3, Rita Kang4, Christopher Hawke2,5, Ahmed Omar6,7, Arane Thavaneswaran1, Nigil Haroon8,9 and Robert D Inman6,10, 1Toronto Western Hospital, Toronto, ON, Canada, 2Allied Health, Toronto Western Hospital, Toronto, ON, Canada, 3Physical Therapy, University of Toronto, Toronto, ON, Canada, 4Patient and Family Education, Toronto Western Hospital, Toronto, ON, Canada, 5Department of Physical Therapy, University of Toronto, Toronto, ON, Canada, 6Rheumatology, Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, 7Rheumatology, University of Toronto, Toronto, ON, Canada, 8Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, 9Medicine, Rheumatology, University of Toronto, Toronto, ON, Canada, 10University of Toronto, Toronto, ON, Canada

    Background/Purpose: The purpose of this study was to Methods:  Fifty-six adult patients with axSpA attending a tertiary academic spondyloarthritis clinic were randomly assigned to one…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology